

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(use as many sheets as necessary)

Sheet

1

of

1

Application Number	Net Yet Assigned 10/734545
Filing Date	Concurrently Herewith
First Named Inventor	Nadji Sourena
Art Unit	N/A 16004
Examiner Name	Net Yet Assigned COLEMAN

Attorney Docket Number 01252/1200687-US1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
--------------------	-----------------------	---	--------------------------------	--	--

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
--------------------	-----------------------	--	--------------------------------	--	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BC		J. Org. Chem, Eunice Chan, et al. "Total Synthesis of (8R)-3-(2-Deoxy- β -D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d]1,3]diazepin-8-ol (Pentostatin), the Potent Inhibitor of Adenosine Deaminase" ^{1a} , 47, 3457-3464, 1982.	
BC		J. Org. Chem, Thien Van Truong et al, "Chirospecific Synthesis of the Tetrahydroimidazodiazepinol Aglycon of Pentostatin and Its Analogues", 58, 6090-6096, 1993.	
BC		Submitted by Seiki Saito, et al., "Diethyl (2S,3R)-2-(N-tert-Butoxycarbonyl)Amino-3-Hydroxysuccinate", Vol. 73, 1995.	
BC		American Chemical Society, David C. Baker, "A Total Synthesis of Pentostatin, the Potent Inhibitor of Adenosine Deaminase", 0002-7863/79/1501-6127, 1979.	
BC		J. Heterocyclic Chem, D.C. Baker et al., "Studies Related to the Total Synthesis of Pentostatin. Approaches to the Synthesis of (8R)-3,6,7,8-Tetrahydroimidazo[4,5-d][diazepin-8-d and N-3 Alkyl Congeners (1a)", Vol 20, 629-634, 1983.	
BC		The Journal of Antibiotics, H.D. Hollis Showalter, et al., "Improved Production of Pentostatin and Identification of Fermentation Comabolites", Vo1. 45, No. 12, 1914-1918, 1982.	
BC		Drugs of the Future, "Antihypertensive Calcium Channel Blocker, Vol. 15, No. 7, 1990.	
BC		J. Am Chem. Soc., Kazuhiro Haraguchi, et al. "Synthesis and Characterization of Oligodeoxynucleotides Containing Formamidopyrimidine Lesions and Nonhydrolyzable Analogues", 124, 3263-3269, 2002.	
BC		American Chemical Society, Brett C. Bookser, et al., "AMP Deaminase Inhibitors.2. Initial Discovery of a Non-Nucleotide Transition-State Inhibitor Series" ¹ , Vol. 43, No. 8, 1495-1507, 2000.	
BC		J. Am. Chem. Soc., Mark D. Erion, et al., "Discovery of AMP Mimetics that Exhibit High Inhibitory Potency and Specificity for AMP Deaminase" 121, 308-319, 1999.	
BC		Nucleosides & Nucleotides, H. Jeanette Thomas, et al., "The Synthesis of Coformycin From 5-Amino-1- β -D-Ribofuranosylimidazole-4-Carboxamide", 5(4) 431-439, 1986.	
BC		Nucleosides & Nucleotides, Mikyung Hong, et al. "Irreversible, Tight-Binding Inhibition of Adenosine Deaminase By Coformycins: Inhibitor Structural Features That Contribute to the Mode of Enzyme Inhibition", 16(7-9), 1053-1057, 1997.	

(W:1012
521200)

Brenda Coleman

Date
Considered

Feb. 19, 2006